UK-based EpilepsyGTx, a biotech focused on research and development of gene therapies to treat refractory epilepsy, has raised $33 million in a Series A financing to advance its lead program EPY201 ...

Privately-held BlossomHill Therapeutics, a US biopharma focused on the design and development of next-generation medicines ...

US AI-focused start-up Formation Bio has entered a deal with Lynk Pharmaceuticals for worldwide rights, excluding Greater ...

The UK government has announced that the 2026 payment rate for newer medicines under the Voluntary Scheme for Branded ...

A senior-level conference focused on the strategies and operating models shaping the next phase of the biopharma industry.

US healthcare giant Johnson & Johnson has announced new data from the investigational Phase III MajesTEC-3 study showing the ...

Clinical-stage biotech D3 Bio announced the completion of a $108 million Series B financing round, adding to the continuous ...

Chinese biotech dominance and opportunities for Western companies to stay competitive have been highlighted in surveys released by clinical research organization ICON.

Generic drugmakers in India are revising pricing plans after Denmark’s Novo Nordisk (NOV: N) slashed costs for its weight-loss injection Wegovy (semaglutide). Companies that had aimed to launch ...

The US regulator has approved Waskyra (etuvetidigene autotemcel), the first gene-correcting therapy for Wiskott-Aldrich ...

The US Food and Drug Administration (FDA) yesterday issued the final guidance, “Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Products, and ...

The US Food and Drug Administration has approved a US-manufactured version of Augmentin XR (amoxicillin-clavulanate potassium) through its new Commissioner’s National Priority Voucher pilot, ...